Microba Life Sciences Ltd
Microba Life Sciences Limited is an Australia-based precision microbiome company.
The business
Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Its Analysis platform is an end-to-end solution for microbiome analysis. Using advanced metagenomic sequencing technology and proprietary bioinformatic tools, it provides precise and comprehensive measurement of the human gut microbiome. Its Discovery Platform is a global databank for microbiome discovery and develops new health solutions from the gut microbiome. Its Therapeutic platform is a repeatable platform for microbial therapeutic leads. Its Diagnostic testing products are MetaXplore and MetaPanel. MetaXplore offers a comprehensive gastrointestinal testing solution. MetaPanel is an advanced gastrointestinal pathogen detection panel.
Small Caps Research
No research on Microba Life Sciences Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise MAP based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Brickworks inks multi-year deal with Santos, Bank of Queensland CEO departs and Pilbara Minerals enters JV with Calix
Australia’s largest bricking company Brickworks (ASX: BKW) has signed a new 11-year gas wholesale supply deal with Santos (ASX: STO) from 2025 – bolstering its east coast brick making operations. Although reduced gas supply and inflationary pressures have driven the deal to a higher price than the previous five-year agreement, Brickworks managing director Lindsay Partridge […]

Sonic Healthcare acquires 20% stake in Microba Life Sciences
Medical diagnostics provider Sonic Healthcare (ASX: SHL) has announced it will spend $17.8 million on the purchase of a 19.99% stake in precision microbiome company Microba Life Sciences (ASX: MAP). Under the terms of the deal, Microba will issue Sonic with new fully paid ordinary shares at $0.26 each to make Sonic a substantial shareholder. […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.